ArticleRheumatology and therapy2026

On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors.

Philip J Mease et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.